Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

209 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Allergic and hypersensitivity condition in the International Patients' Summary (IPS) standard: The need of updates through the International Classification of Diseases (ICD)-11.
Tanno LK, Perie A, Bernstein JA, Sublett JL, Davtyan K, Berard F, Pawankar R, Valentin Rostan M, Chong H, Yañez A, Ansontegui IJ, Ebisawa M, Wong GWK, Morais-Almeida M, Martin B, Briand Y, Demoly P; American Academy of Allergy Asthma & Immunology (AAAAI); American College of Allergy Asthma and Immunology (ACAAI); Asia Pacific Association of Allergy Asthma and Clinical Immunology (APAAACI); French Allergy Society (SFA); French WHO Collaborating Centre; WHO Regional Office for Europe; Latin American Society of Allergy and Immunology (SLAAI); Montpellier WHO Collaborating Centre; World Allergy Organization (WAO). Tanno LK, et al. Among authors: berard f. World Allergy Organ J. 2024 Aug 20;17(8):100921. doi: 10.1016/j.waojou.2024.100921. eCollection 2024 Aug. World Allergy Organ J. 2024. PMID: 39253619 Free PMC article. Review.
A quick access to information on influenza burden and prevention in Lyon university hospital: A prospective QR code-based information campaign in 2022-2023.
Khanafer N, Oudot S, Maligeay M, Planckaert C, Mena C, Mandel NT, Bouhalila R, Ader F, Berard F, Bouhour F, Chapurlat R, Charriere S, Confavreux C, Devouassoux G, Disse E, Fouque D, Ghesquieres H, Hyvert S, Jolivot A, Durand A, Martin-Gaujard G, Mornex JF, Nicolino M, André-Obadia N, Raverot G, Reix P, Ruffion A, Seve P, Hermann R, Zoulim F, Clamens J, Ayala MP, Vanhems P. Khanafer N, et al. Among authors: berard f. Vaccine. 2024 Aug 30;42(21):126160. doi: 10.1016/j.vaccine.2024.126160. Epub 2024 Jul 26. Vaccine. 2024. PMID: 39068066 Free article.
Comprehensive Ophthalmological Evaluation in Atopic Dermatitis.
Valeille A, Ouilhon C, Subtil F, Hacard F, Jaulent C, Bérard F, Nicolas JF, Fauquert JL, Nosbaum A. Valeille A, et al. Among authors: berard f. Dermatology. 2024;240(3):434-442. doi: 10.1159/000536233. Epub 2024 Feb 14. Dermatology. 2024. PMID: 38354719
Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.
Maurer M, Ensina LF, Gimenez-Arnau AM, Sussman G, Hide M, Saini S, Grattan C, Fomina D, Rigopoulos D, Berard F, Canonica GW, Rockmann H, Irani C, Szepietowski JC, Leflein J, Bernstein JA, Peter JG, Kulthanan K, Godse K, Ardusso L, Ukhanova O, Staubach P, Sinclair R, Gogate S, Thomsen SF, Tanus T, Ye YM, Burciu A, Barve A, Modi D, Scosyrev E, Hua E, Letzelter K, Varanasi V, Patekar M, Severin T; PEARL-1 and PEARL-2 trial investigators. Maurer M, et al. Among authors: berard f. Lancet. 2024 Jan 13;403(10422):147-159. doi: 10.1016/S0140-6736(23)01684-7. Epub 2023 Nov 23. Lancet. 2024. PMID: 38008109 Clinical Trial.
Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patients.
Chebani R, Lombart F, Chaby G, Dadban A, Debarbieux S, Viguier MA, Ingen-Housz-Oro S, Pham-Ledard A, Bedane CR, Picard-Dahan C, Berthin C, Dereure O, Konstantinou MP, Castel M, Jouen F, Joly P, Seta V, Duvert-Lehembre S, Le Roux C, Quereux G, Sassolas B, Brenaut E, Sin C, Richard MA, Bérard F, Giusti D, Belmondo T, Gille T, Caux F, Prost-Squarcioni C, Grootenboer-Mignot S, Alexandre M; French Study Group on Autoimmune Bullous Diseases. Chebani R, et al. Among authors: berard f. Br J Dermatol. 2024 Jan 23;190(2):258-265. doi: 10.1093/bjd/ljad369. Br J Dermatol. 2024. PMID: 37792727
Hypersensitivity infusion-associated reactions induced by enzyme replacement therapy in a cohort of patients with late-onset Pompe disease: An experience from the French Pompe Registry.
Lessard LER, Tard C, Salort-Campana E, Sacconi S, Béhin A, Bassez G, Orlikowski D, Merle P, Nollet S, Gallay L, Bérard F, Robinson P, Bouhour F, Laforêt P. Lessard LER, et al. Among authors: berard f. Mol Genet Metab. 2023 Jul;139(3):107611. doi: 10.1016/j.ymgme.2023.107611. Epub 2023 May 19. Mol Genet Metab. 2023. PMID: 37285781 Free article.
The efficacy of therapeutic plasma exchange in COVID-19 patients on endothelial tightness in vitro is hindered by platelet activation.
Ebermeyer T, Hequet O, Berard F, Prier A, Eyraud MA, Arthaud CA, Heestermans M, Duchez AC, Guironnet-Paquet A, Berthelot P, Cognasse F, Hamzeh-Cognasse H. Ebermeyer T, et al. Among authors: berard f. Front Cardiovasc Med. 2023 May 4;10:1094786. doi: 10.3389/fcvm.2023.1094786. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 37215546 Free PMC article.
209 results